KRAS and cancer: Despite the availability of therapeutic agents for targeting KRAS G12C mutations and positive clinical outcomes, patients and physicians have to deal with the possibility of cancer cells developing resistance to sotorasib and adagrasib during clinical trials and actual treatment.